

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**COMMON SPLENDOR INTERNATIONAL
HEALTH INDUSTRY GROUP LIMITED**

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

**LAPSE OF THE PROPOSED ISSUANCE OF
NEW SHARES UNDER GENERAL MANDATE
TO GEM GLOBAL YIELD FUND LLC SCS**

Reference is made to the announcement of Common Splendor International Health Industry Group Limited (the “**Company**”) dated 16 September 2015 in relation to the proposed issue of new shares under General Mandate (the “**Announcement**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, subject to the satisfaction of the Conditions Precedent, on any Trading Day during the Commitment Period, the Company shall be entitled (without any obligation) at its sole discretion to issue a Placement Notice to the Investor, which specifies the Placement Amount and the Fixed Market Price. As disclosed in the Announcement, the Investor, namely GEM Global Yield Fund LLC SCS, and the Investment Adviser, namely GEM Investments America, LLC, are engaged in the regular business of making passive investments in corporate entities globally. Based on the information provided by the Investor, the Investment Adviser, its affiliated companies and the Investor comprise a privately held US-based equity investment group that was founded in 1991 and manages a diverse set of investment vehicles across the world. The Company wishes to announce that it did not issue any Placement Notice pursuant to the Agreement, and accordingly, the Company did not proceed with the proposed placement of new Shares.

In 2015 and 2016, the Company explored and proceeded with alternative means of fund raising, such as the issuance of bonds and convertible bonds by the Company. Accordingly, the Board considers that the lapse of the said proposed placement of new Shares has no material adverse impact on the existing business operation and financial position of the Group.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Lam King Ho
Company Secretary

Hong Kong, 21 December 2016

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Bai Yinghai as non-executive Directors; and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Lam Chi Wing as independent non-executive Directors.